Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced today it has opened HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, with Australia being the first region to enroll patients to date. In addition, the company has received clearance from the Food and Drug Administration (FDA) for the Investigational New Drug (IND) Application for THOR-707, paving the way for patient enrollment to proceed in the U.S. The single agent and combination arms of the trial are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of THOR-707 in patients with advanced or metastatic solid tumors.